Navigation Links
Varian, Inc. Reports Fourth Quarter 2009 Results
Date:11/4/2009

=========== =========== NON-GAAP (ADJUSTED) FINANCIAL MEASURES (see also attached reconciliations of GAAP to Adjusted results for each of these measures): (1) $441,730 on an adjusted basis excluding $6,117 in acquisition- related intangible amortization, $131 in acquisition-related inventory write-up amortization and $4,076 in restructuring and other related costs. (2) $224,255 on an adjusted basis excluding $9,155 in costs related to the pending acquisition by Agilent, $1,118 in acquisition-related intangible amortization and $4,754 in restructuring and other related costs. (3) $55,583 on an adjusted basis excluding $842 in restructuring and other related costs. (4) $85,176 on an adjusted basis excluding the adjustments described in items (1) - (3) above. (5) $27,294 on an adjusted basis excluding the tax impact of the adjustments described in items (1) - (3) above. (6) $58,046 and $2.01 per share, respectively, on an adjusted basis excluding the adjustments (net of related tax effects) described in items (1) - (3) above. (7) $550,465 on an adjusted basis excluding $6,547 in acquisition-related intangible amortization, $1,408 in acquisition-related inventory write-up amortization and $1,641 in restructuring and other related costs. (8) $273,072 on an adjusted basis excluding $1,825 in acquisition-related intangible amortization and $2,581 in restructuring and other related costs. (9) $70,556 on an adjusted basis excluding $1,254 in restructuring and other related costs. (10) $0 on an adjusted basis excluding $1,703 related to an acquisition- related in-process research and development charge. (11) $118,422 on an adjusted basis excluding the adjustments described in items (7) - (10) above. (12) $0 on an adjusted basis exc
'/>"/>
SOURCE Varian, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

Related medicine technology :

1. Varian, Inc. to Release Fourth Quarter and Full Fiscal Year 2009 Financial Results
2. Varian, Inc. Delivers a Productivity Increase of Up to 100% With Its 710-ES Series ICP-OES
3. 96-Well Filtration Plate From Varian, Inc. Improves Sensitivity and Precision for Trace Bio-Analysis by LC/MS
4. Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent
5. Medivation Reports Third Quarter 2009 Financial Results and Provides Corporate Update
6. Cambrex Reports Third Quarter 2009 Results
7. Regeneron Reports Third Quarter 2009 Financial and Operating Results
8. Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C
9. Uroplasty Reports Results for Second Quarter FY2010
10. Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD
11. Mettler-Toledo International Inc. Reports Third Quarter 2009 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Tegra Medical is very pleased to announce the appointment ... Chief Executive Officer.  Mark was promoted from his current role ... company,s four facilities in Massachusetts , ... Tegra Medical in 2012 with 20+ years of broad-based operations, ...
(Date:1/15/2014)... PHILADELPHIA , Jan. 15, 2014  Echo Therapeutics, Inc. ... company developing its Symphony® CGM System as a non-invasive, ... Robert F. Doman , Executive Chairman and Interim CEO ... Capital Markets, Tenth Annual Equity Conference. ...
(Date:1/15/2014)... 15, 2014  According to Millennium Research Group (MRG), ... the United States and ... will expand moderately through 2022, with embolization particles ... increasing interest in drug-eluting beads (DEBs) and radioembolization ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... found, results showed CYPHER(R) Stent ... had lower mortality and heart attack rates, ... patient data from a two-year randomized controlled trial comparing,the ... no,statistically significant differences in safety outcomes between the two,drug- ...
... Clinical investigators at the,European Society of Cardiology Congress ... Coronary Stent continued to,provide clinical benefits compared to a ... years of follow-up with no differences in safety. ... arm of the,study continued to be significantly less likely ...
Cached Medicine Technology:Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent 2Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent 3Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent 4Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety 2Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety 3Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety 4Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety 5
(Date:4/18/2014)... turns 160 years of neuroanatomy on its head. , ... essential for the fast transmission of impulses along the ... thought, according to a new work lead by Professor ... and the University,s Department of Stem Cell and Regenerative ... Department of Molecular and Cellular Biology. , "Myelin is ...
(Date:4/18/2014)... April 18, 2014) Benaroya Research Institute at Virginia ... blocking a particular molecule in metastatic breast cancer reduces ... of lung metastases. BRI scientists have found in models ... tumors by 60 - 80 percent and can keep ... The $1.8 million five-year grant comes from the National ...
(Date:4/18/2014)... . A ... A team led by Ludwik Leibler from the Laboratoire ... Letourneur from the Laboratoire Recherche Vasculaire Translationnelle (INSERM/Universits Paris ... principle of adhesion by aqueous solutions of nanoparticles can ... tissues. This easy-to-use gluing method has been tested on ...
(Date:4/17/2014)... in non-cancerous prostate tissue may have nearly twice the ... no inflammation, according to results of a new study ... Center. , The link between persistent inflammation and cancer ... cancer those with a Gleason score between 7 ... aggressive and rapidly growing prostate cancers. , "What we,ve ...
(Date:4/17/2014)... of the most popular vaccine brands for children may ... be overlooking some cost factors when choosing vaccines, driving ... option, according to a new study by University of ... can be driven by numerous factors," says Sheldon H. ... of computer science and of mathematics at the U. ...
Breaking Medicine News(10 mins):Health News:Finding turns neuroanatomy on its head 2Health News:Finding turns neuroanatomy on its head 3Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study recalculates costs of combination vaccines 2
... pink race gear on e Bay in favor of Susan ... Awareness month and pink is// the symbolic color of Breast ... Racing to create exclusive warriors in pink livery with exclusive ... the eBay auction. ,Parts of the Warrior in ...
... a team of researchers from the Edinburgh University, the risk ... a variant of a gene called// neuregulin. ,This ... high risk of developing schizophrenia were monitored for 10 years ... the volunteers had 2 or more relatives affected by this ...
... packets of counterfeit condoms of Durex best-selling 'extra safe' range ... ,A Durex spokeswoman stated that the company could not 'guarantee ... that were on sale in UK was also unknown,These counterfeits ... When tests were conducted at the company's laboratories it was ...
... which could protect children from meningococcal disease is being ... disease has not been// available. ,The researchers, ... Child Health Research and Princess Margaret Hospital for Children, ... meningococcal B strain which is the most common. It is ...
... Monday called for fast tracking of the approval ... effective against extremely drug resistant// tuberculosis(XDR-TB) which is ... ,MSF otherwise called Doctors Without Borders(DWB) has ... Food and Drug Administraton(USFDA) and European Medicines Agency ...
... must have spice in every Indian home now finds itself ... uses to fight// many tubborn inflammations and degenerative disorders thus ... scripts of Ayurveda. ,According to a recent study ... Janet L. Funk, MD, working with Barbara N. Timmermann, PhD ...
Cached Medicine News:Health News:Gene Variant associated with Schizophrenia identified 2Health News:Faster Approval Procedures Urged For New TB Drugs 2
... product line has the right product for ... and from intubated patients to patients with ... both anesthesia and critical care applications., ... protection for patients and staff members. This ...
Passive heat and moisture exchangers for respiratory applications....
Passive heat and moisture exchangers for respiratory applications....
Ballard trach care HMES and filters, tv 500, HME...
Medicine Products: